Suzhou, China

Qi Kong

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Qi Kong - Innovator in Carcinogenic Research

Introduction

Qi Kong is a notable inventor based in Suzhou, China. He has made significant contributions to the field of carcinogenic research, particularly through his innovative work involving human keratinocytes. His research focuses on understanding the effects of arsenic metabolites on skin cells, which has important implications for cancer studies.

Latest Patents

Qi Kong holds a patent titled "Dimethylarsinous acid-induced malignantly transformed cell line of human keratinocytes and use thereof." This invention relates to the establishment of a model that helps in identifying the carcinogenicity of arsenic methylated metabolites. The patent describes a method where human keratinocytes are persistently exposed to low doses of dimethylarsinous acid, leading to the creation of a malignantly transformed cell model. This model is crucial for studying the carcinogenic mechanisms associated with arsenic exposure.

Career Highlights

Qi Kong is affiliated with Soochow University, where he conducts his research. His work has garnered attention for its innovative approach to understanding cancer mechanisms. With a focus on the long-term effects of low-dose arsenic exposure, his research provides valuable insights into skin cell malignancy.

Collaborations

Qi Kong collaborates with colleagues such as Yan An and Rui Yan, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

In summary, Qi Kong is a prominent inventor whose work in carcinogenic research is paving the way for new understandings of cancer mechanisms related to arsenic exposure. His contributions are vital for advancing the field and improving cancer research methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…